Combating Illicit Xylazine Act

S 993, the Combating Illicit Xylazine Act, makes the illicit distribution and use of xylazine illegal under federal drug laws. The bill defines xylazine broadly (including multiple chemical variants) and prohibits all human use or non-lici distribution, while allowing only veterinary and pharmaceutical uses approved under existing regulations. It requires the DEA and FDA to report to Congress within a year on xylazine's spread and impacts, with a follow-up report four years later. This directly affects drug traffickers and distributors adding xylazine to illicit drugs like fentanyl, aiming to address a public health threat linked to severe health consequences including necrosis.